14 results on '"Chiarello, Carmelina"'
Search Results
2. Regression of Cardiac Rhabdomyomas Producing a Severe Aortic Stenosis: Case Report and Discussion of the Literature
- Author
-
Fesslova, Vlasta M. E., primary, Evangelista, Martina, additional, Piazza, Luciane, additional, Saracino, Antonio, additional, Andronache, Andreea, additional, Chiarello, Carmelina, additional, Varrica, Alessandro, additional, Giamberti, Alessandro, additional, and Frigiola, Alessandro, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Modern tools in congenital heart disease imaging and procedure planning: a European survey
- Author
-
Iannotta, Marvin, primary, d’Aiello, Fabio Angelo, additional, Van De Bruaene, Alexander, additional, Caruso, Rosario, additional, Conte, Gianluca, additional, Ferrero, Paolo, additional, Bassareo, Pier Paolo, additional, Pasqualin, Giulia, additional, Chiarello, Carmelina, additional, Militaru, Constantin, additional, Giamberti, Alessandro, additional, Bognoni, Ludovica, additional, and Chessa, Massimo, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload
- Author
-
Polidovitch, Nazari, Yang, Sibao, Sun, Huan, Lakin, Robert, Ahmad, Faiyaz, Gao, Xiaodong, Turnbull, Patrick C., Chiarello, Carmelina, Perry, Christopher G.R., Manganiello, Vincent, Yang, Ping, and Backx, Peter H.
- Published
- 2019
- Full Text
- View/download PDF
5. Prenatal Diagnosis and Postnatal Outcomes of Left Brachiocephalic Vein Abnormalities: Systematic Review
- Author
-
Gaeta, Gerarda, primary, Fesslova, Vlasta, additional, Villanacci, Roberta, additional, Morano, Danila, additional, Candiani, Massimo, additional, Pozzoni, Mirko, additional, Papale, Margherita, additional, Spinillo, Silvia Lina, additional, Chiarello, Carmelina, additional, and Cavoretto, Paolo Ivo, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIA‐R)
- Author
-
Sinning, Christoph, Zengin, Elvin, Diller, Gerhard-Paul, Onorati, Francesco, Castel, María-Angeles, Petit, Thibault, Chen, Yih-Sharng, Lo Rito, Mauro, Chiarello, Carmelina, Guillemain, Romain, Coniat, Karine Nubret-Le, Magnussen, Christina, Knappe, Dorit, Becher, Peter Moritz, Schrage, Benedikt, Smits, Jacqueline M., Metzner, Andreas, Knosalla, Christoph, Schoenrath, Felix, Miera, Oliver, Cho, Mi-Young, Bernhardt, Alexander, Weimann, Jessica, Goßling, Alina, Terzi, Amedeo, Amodeo, Antonio, Alfieri, Sara, Angeli, Emanuela, Ragni, Luca, Napoleone, Carlo Pace, Gerosa, Gino, Pradegan, Nicola, Rodrigus, Inez, Dumfarth, Julia, de Pauw, Michel, François, Katrien, Van Caenegem, Olivier, Ancion, Arnaut, Van Cleemput, Johan, Miličić, Davor, Moza, Ajay, Schenker, Peter, Thul, Josef, Steinmetz, Michael, Warnecke, Gregor, Ius, Fabio, Freyt, Susanne, Avsar, Murat, Sandhaus, Tim, Haneya, Assad, Eifert, Sandra, Saeed, Diyar, Borger, Michael, Welp, Henryk, Ablonczy, László, Schmack, Bastian, Ruhparwar, Arjang, Naito, Shiho, Hua, Xiaoqin, Fluschnik, Nina, Nies, Moritz, Keil, Laura, Senftinger, Juliana, Ismaili, Djemail, Kany, Shinwan, Csengeri, Dora, Cardillo, Massimo, Oliveti, Alessandra, Faggian, Giuseppe, Dorent, Richard, Jasseron, Carine, Blanco, Alicia Pérez, Márquez, José Manuel Sobrino, López-Vilella, Raquel, García-Álvarez, Ana, López, María Luz Polo, Rocafort, Alvaro Gonzalez, Fernández, Óscar González, Prieto-Arevalo, Raquel, Zatarain-Nicolás, Eduardo, Blanchart, Katrien, Boignard, Aude, Battistella, Pascal, Guendouz, Soulef, Houyel, Lucile, Para, Marylou, Flecher, Erwan, Gay, Arnaud, Épailly, Éric, Dambrin, Camille, Lam, Kaitlyn, Ka-lai, Cally Ho, Cho, Yang Hyun, Choi, Jin-Oh, Kim, Jae-Joong, Coats, Louise, Crossland, David Steven, Mumford, Lisa, Hakmi, Samer, Sivathasan, Cumaraswamy, Fabritz, Larissa, Schubert, Stephan, Gummert, Jan, Hübler, Michael, Jacksch, Peter, Zuckermann, Andreas, Laufer, Günther, Baumgartner, Helmut, Giamberti, Alessandro, Reichenspurner, Hermann, and Kirchhof, Paulus
- Subjects
Heart Defects, Congenital ,Adult ,Cardiac & Cardiovascular Systems ,Heart Defects, Congenital / therapy ,Waiting Lists ,Study Designs ,Medizin ,Heart transplantation ,Heart Defects, Congenital / complications ,MANAGEMENT ,Diseases of the circulatory (Cardiovascular) system ,Humans ,ESC GUIDELINES ,Heart Failure / therapy ,Adults with congenital heart disease, Arrhythmia, Heart failure, Heart transplantation, Lung transplantation, Ventricular assist device ,Retrospective Studies ,GENERAL-POPULATION ,Heart Failure ,OUTCOMES ,Study Design ,Science & Technology ,TRANSPLANTATION ,MORTALITY ,Heart Failure / epidemiology ,Heart Transplantation / adverse effects ,ADULTS ,ASSOCIATION ,EUROPEAN-SOCIETY ,Lung transplantation ,Heart Failure / etiology ,RC666-701 ,Cardiovascular System & Cardiology ,Ventricular assist device ,Heart Transplantation ,Heart Defects, Congenital / epidemiology ,Adults with congenital heart disease ,Human medicine ,Life Sciences & Biomedicine ,Arrhythmia ,TASK-FORCE - Abstract
ESC heart failure 8(6), 5542-5550 (2021). doi:10.1002/ehf2.13574, Published by Wiley, Chichester
- Published
- 2021
7. Prevalence of Congenital Heart Defects in Pregnancies Conceived by Assisted Reproductive Technology: A Cohort Study
- Author
-
Galdini, Alessandro, primary, Fesslova, Vlasta M. E., additional, Gaeta, Gerarda, additional, Candiani, Massimo, additional, Pozzoni, Mirko, additional, Chiarello, Carmelina, additional, and Cavoretto, Paolo Ivo, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Negative feedback regulation of Homer 1a on norepinephrine-dependent cardiac hypertrophy
- Author
-
Chiarello, Carmelina, Bortoloso, Elena, Carpi, Andrea, Furlan, Sandra, and Volpe, Pompeo
- Published
- 2013
- Full Text
- View/download PDF
9. Outcomes and Quality of Life After Ross Reintervention: Would You Make the Same Choice Again?
- Author
-
Varrica, Alessandro, primary, Caldaroni, Federica, additional, Saitto, Guglielmo, additional, Satriano, Angela, additional, Lo Rito, Mauro, additional, Chiarello, Carmelina, additional, Ranucci, Marco, additional, Frigiola, Alessandro, additional, and Giamberti, Alessandro, additional
- Published
- 2020
- Full Text
- View/download PDF
10. Study design and rationale of the p A tients p R esen T ing with c O ngenital hea R t d I se A se R egister (ARTORIA‐R).
- Author
-
Sinning, Christoph, Zengin, Elvin, Diller, Gerhard‐Paul, Onorati, Francesco, Castel, María‐Angeles, Petit, Thibault, Chen, Yih‐Sharng, Lo Rito, Mauro, Chiarello, Carmelina, Guillemain, Romain, Coniat, Karine Nubret‐Le, Magnussen, Christina, Knappe, Dorit, Becher, Peter Moritz, Schrage, Benedikt, Smits, Jacqueline M., Metzner, Andreas, Knosalla, Christoph, Schoenrath, Felix, and Miera, Oliver
- Subjects
CONGENITAL heart disease ,HEART failure - Abstract
Aim: Due to improved therapy in childhood, many patients with congenital heart disease reach adulthood and are termed adults with congenital heart disease (ACHD). ACHD often develop heart failure (HF) as a consequence of initial palliative surgery or complex anatomy and subsequently require advanced HF therapy. ACHD are usually excluded from trials evaluating heart failure therapies, and in this context, more data about heart failure trajectories in ACHD are needed to guide the management of ACHD suffering from HF. Methods and results: The pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIA‐R) will collect data from ACHD evaluated or listed for heart or heart‐combined organ transplantation from 16 countries in Europe and the Asia/Pacific region. We plan retrospective collection of data from 1989–2020 and will include patients prospectively. Additional organizations and hospitals in charge of transplantation of ACHD will be asked in the future to contribute data to the register. The primary outcome is the combined endpoint of delisting due to clinical worsening or death on the waiting list. The secondary outcome is delisting due to clinical improvement while on the waiting list. All‐cause mortality following transplantation will also be assessed. The data will be entered into an electronic database with access to the investigators participating in the register. All variables of the register reflect key components important for listing of the patients or assessing current HF treatment. Conclusion: The ARTORIA‐R will provide robust information on current management and outcomes of adults with congenital heart disease suffering from advanced heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Italian survey on cardiac surgery for adults with congenital heart disease: which surgery, where and by whom?
- Author
-
Giamberti, Alessandro, Chessa, Massimo, Chiarello, Carmelina, Cipriani, Adriano, Carotti, Adriano, Galletti, Lorenzo, Gargiulo, Gaetano, Marianeschi, Stefano Maria, Napoleone, Carlo Pace, Padalino, Massimo, Perri, Gianluigi, Luciani, Giovanni Battista, and Surgery, Congenital Domain of the Italian Society of Cardiac
- Published
- 2019
- Full Text
- View/download PDF
12. Irx3 is required for postnatal maturation of the mouse ventricular conduction system
- Author
-
Kim, Kyoung-Han, primary, Rosen, Anna, additional, Hussein, Samer M. I., additional, Puviindran, Vijitha, additional, Korogyi, Adam S., additional, Chiarello, Carmelina, additional, Nagy, Andras, additional, Hui, Chi-chung, additional, and Backx, Peter H., additional
- Published
- 2016
- Full Text
- View/download PDF
13. Role of the scaffolding protein Homer 1a in cardiac hypertrophy
- Author
-
Chiarello, Carmelina
- Subjects
Homer 1a protein ,Settore BIO/10 - Biochimica ,BIO/10 Biochimica - Abstract
Homer proteins are a family of scaffolding proteins involved in many intracellular signaling pathways, in both excitable and non-excitable cells. These proteins participate in the assembly and regulation of functional signaling complexes, facilitating the cross-talk between surface membrane receptors and channels in the membranes of intracellular compartments (Worley PF. et al., 2007). Homer proteins are constitutively expressed in the brain, where their scaffolding function is important for a variety of neuronal processes, such as intracellular Ca2+ homeostasis, synaptic plasticity associated with learning and memory in the mature brain, and neuronal development of the embryonic brain (Xiao B. et al., 1998; Worley PF. et al., 2007; Foa L. et al., 2009). Among the Homer splice variants, Homer 1a isoform acts as a natural dominant-negative by disassembling signalling complexes mediated by other Homer isoforms. The Homer 1a gene is transcribed as an immediate early gene (IEG), in neuronal cells its expression is low under normal conditions and increases rapidly after neuronal activation (Brakeman PR. et al., 1997). Homers proteins are also expressed in cardiac muscle, but their regulation and function remain still poorly understood. Despite their important role as regulators of multimeric signalling complex in nervous system, few reports have focused on the role of Homers in the heart. It has been reported that mRNA coding for Homer 1a rapidly and transiently increases in neonatal cardiomyocytes upon stimulation with either endothelin-1 (ET1) or other hypertrophic agonists (Kawamoto T. et al., 2006). The Homer 1a protein levels are also up-regulated following AngII-induced hypertrophy in neonatal cardiomyocytes (Guo WG. et al., 2010). Recently, it has been demonstrated that the variant Homer 1b/c positively regulates α1-adrenergic dependent hypertrophy, whereas Homer 1a is able to antagonize such effect (Grubb DR. et al., 2011). This study investigated the role of Homer 1a in the cardiac hypertrophic program. Our working hypothesis is that Homer 1a may be one of the molecular modulators of cardiac hypertrophy. For this purpose, we studied the presence, sub-cellular distribution and function of Homer1a in cardiac muscle. Under resting conditions we found that Homer 1a is constitutively expressed in cardiac muscle of both mouse and rat and in HL-1 cells (a specific cardiac cell line). In addition, using immunofluorescence confocal microscopy of adult rat heart sections, we showed that Homer 1a displays a peculiar localization: it is sarcomeric and peri-nuclear. We also analyzed Homer 1a expression under hypertrophic conditions. For this purpose, we used rat neonatal cardiomyocytes stimulated with the adrenergic agonist norepinephrine (NE). A significant increase in both Homer1a mRNA and protein was found after NE stimulation, whereas Homer 1b/c (a different Homer 1 isoform) expression remained unchanged. In this hypertrophic cellular model, we studied the adrenergic pathways involved in NE-inducted Homer 1a up-regulation by using specific α1- and β- adrenergic receptor blockers (prazosin and propranolol, respectively). The results showed that prazosin - but not propranolol - drastically reduced NE-induced up-regulation of Homer 1a mRNA, demonstrating that the α1-adrenergic pathway is involved. The effect of hypertrophic stimulation on Homer 1a expression was also confirmed in NE-stimulated HL-1 cardiomyocytes. In this cell line we found that 1 hour after NE stimulation Homer 1a content increased by a factor of 2.5. Overall, these results confirm our working hypothesis and demonstrate the involvement of Homer 1a in the α1-adrenergic pathway leading to cardiac hypertrophy. In the second part of the study we analyzed the effects of Homer 1a over-expression monitoring different hypertrophic markers, such as MAPK/ERK1/2 phosphorylation, NFAT nuclear translocation, ANF-promoter activity and increase in cell size. The results showed that during NE stimulation Homer 1a modulated many of them (except for NFAT nuclear translocation that did not appear to be affected by Homer 1a over-expression), whereas under resting conditions Homer 1a over-expression per sè was ineffective. In particular, we found that, in NE-stimulated HL-1 cells, over-expressed Homer 1a significantly reduced phosphorylation levels of ERK1/2 by about 40%, negatively modulating MAPK pathway. As regards the ANF promoter activity, this activity was significantly reduced by about 20% in NE-stimulated Homer 1a over-expressing cells. In order to verify the specificity of the Homer 1a effect on ANF, we performed the same experiment over-expressing Homer 1c and we found that, unlike Homer 1a, Homer 1c did not modulate the activity of ANF promoter in NE-stimulated HL-1 cells. Subsequently, we assessed the effect of Homer 1a over-expression on increase in cell size. The results obtained showed that Homer 1a counteracted the increase in NE-stimulated cell size. Finally, a preliminary analysis, in vivo, of Homer 1a expression was performed in three hypertrophic models, i.e. mice with chronic transverse aortic constriction, transgenic mice over-expressing Gαq and rats treated with monocrotaline. At variance with results observed in cellular models in vitro, in these models Homer 1a expression did not result affected by hypertrophic conditions, at least in the time span under investigation. However, for this approach in vivo, a broad time-course is needed and, therefore, further analyses are required. In summary, our data on Homer 1a presence and sub-cellular localization in cardiac tissue demonstrate that Homer 1a is constitutively expressed and displays a sarcomeric and peri-nuclear distribution. In our cellular models in vitro, Homer 1a up-regulation is an early event of the NE-induced hypertrophy and, as inferred from gain-of function studies, Homer 1a isoform antagonizes initiation and development of NE-induced events leading to α1-adrenergic-dependent hypertrophy. In conclusion, our results in vitro indicate that Homer 1a is inserted into a negative feedback mechanism in which acts as negative molecular modulator, counteracting early steps of hypertrophy. However, further studies are needed to elucidate the mechanisms underlying this process.
- Published
- 2013
14. Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIA-R).
- Author
-
Sinning C, Zengin E, Diller GP, Onorati F, Castel MA, Petit T, Chen YS, Lo Rito M, Chiarello C, Guillemain R, Coniat KN, Magnussen C, Knappe D, Becher PM, Schrage B, Smits JM, Metzner A, Knosalla C, Schoenrath F, Miera O, Cho MY, Bernhardt A, Weimann J, Goßling A, Terzi A, Amodeo A, Alfieri S, Angeli E, Ragni L, Napoleone CP, Gerosa G, Pradegan N, Rodrigus I, Dumfarth J, de Pauw M, François K, Van Caenegem O, Ancion A, Van Cleemput J, Miličić D, Moza A, Schenker P, Thul J, Steinmetz M, Warnecke G, Ius F, Freyt S, Avsar M, Sandhaus T, Haneya A, Eifert S, Saeed D, Borger M, Welp H, Ablonczy L, Schmack B, Ruhparwar A, Naito S, Hua X, Fluschnik N, Nies M, Keil L, Senftinger J, Ismaili D, Kany S, Csengeri D, Cardillo M, Oliveti A, Faggian G, Dorent R, Jasseron C, Blanco AP, Márquez JMS, López-Vilella R, García-Álvarez A, López MLP, Rocafort AG, Fernández ÓG, Prieto-Arevalo R, Zatarain-Nicolás E, Blanchart K, Boignard A, Battistella P, Guendouz S, Houyel L, Para M, Flecher E, Gay A, Épailly É, Dambrin C, Lam K, Ka-Lai CH, Cho YH, Choi JO, Kim JJ, Coats L, Crossland DS, Mumford L, Hakmi S, Sivathasan C, Fabritz L, Schubert S, Gummert J, Hübler M, Jacksch P, Zuckermann A, Laufer G, Baumgartner H, Giamberti A, Reichenspurner H, and Kirchhof P
- Subjects
- Adult, Humans, Retrospective Studies, Waiting Lists, Heart Defects, Congenital complications, Heart Defects, Congenital epidemiology, Heart Defects, Congenital therapy, Heart Failure epidemiology, Heart Failure etiology, Heart Failure therapy, Heart Transplantation adverse effects
- Abstract
Aim: Due to improved therapy in childhood, many patients with congenital heart disease reach adulthood and are termed adults with congenital heart disease (ACHD). ACHD often develop heart failure (HF) as a consequence of initial palliative surgery or complex anatomy and subsequently require advanced HF therapy. ACHD are usually excluded from trials evaluating heart failure therapies, and in this context, more data about heart failure trajectories in ACHD are needed to guide the management of ACHD suffering from HF., Methods and Results: The pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIA-R) will collect data from ACHD evaluated or listed for heart or heart-combined organ transplantation from 16 countries in Europe and the Asia/Pacific region. We plan retrospective collection of data from 1989-2020 and will include patients prospectively. Additional organizations and hospitals in charge of transplantation of ACHD will be asked in the future to contribute data to the register. The primary outcome is the combined endpoint of delisting due to clinical worsening or death on the waiting list. The secondary outcome is delisting due to clinical improvement while on the waiting list. All-cause mortality following transplantation will also be assessed. The data will be entered into an electronic database with access to the investigators participating in the register. All variables of the register reflect key components important for listing of the patients or assessing current HF treatment., Conclusion: The ARTORIA-R will provide robust information on current management and outcomes of adults with congenital heart disease suffering from advanced heart failure., (© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.